Eli Lilly's Experimental Weight-Loss Drug Eloralintide Achieves Over 11% Body Weight Reduction in Early Trials

Gelonghui June 16 | A recent investor report released by investment bank Cantor Fitzgerald showed that in early studies, Eli Lilly's experimental weight-loss drug, Elinopeptide, helped some patients lose 11.5% of their body weight within 12 weeks. Analysts said that the weight loss data for Eli Lilly’s Elinopeptide was better than Roche and Zealand's Petrilin peptide, adding that the data was also significantly better than Novo Nordisk's monotherapy.